The effects of second-hand smoke on biological processes important in atherogenesis

Login or register to view PDF.

Atherosclerosis is an inflammatory disease that accounts for nearly 50% of deaths in western societies,1 Initiation of atherosclerotic plaque formation is a complex process. It involves secretion of chemokines such as the Monocyte Chemoattractant Protein├óÔé¼ÔÇ£1 (MCP-1)1-4 and expression of adhesion molecules on the surface of monocytes and endothelial cells.5-7 Circulating monocytes are recruited to sites of injured endothelial cells, adhere to them, and migrate into the subendothelial space. Monocytes in the arterial wall differentiate into activated macrophages that are efficient scavengers of oxidized low density lipoprotein (LDL). When exposed to large amounts of oxidized LDL, these macrophages accumulate large amounts of cholesteryl esters in lipid droplets and become \foam cells\" that form \"fatty streaks\", the precursors of more complicated atherosclerotic plaques.8,9


  1. Glass CK, Witztum JL: Atherosclerosis. the road ahead. Cell 2001, 104:503-516.
  2. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
  3. Bruce I, McNally J, Bell A: Enhanced monocyte generation of reactive oxygen species in primary systemic vasculitis. J Rheumatol 1997, 24:2364-2370.
  4. Terkeltaub R, Boisvert WA, Curtiss LK: Chemokines and atherosclerosis. Curr Opin Lipidol 1998, 9:397-405.
  5. Cybulsky MI, Gimbrone MA Jr.: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
  6. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL: PSelectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000, 191:189-194.
  7. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD: The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998, 102:145-152.
  8. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A: Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996, 271:8837-8842.
  9. Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
  10. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
  11. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr.: Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998, 97:1876-1887.
  12. Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999, 100:1481-1492.
  13. Smith CJ, Fischer TH: Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis 2001, 158:257-267.
  14. Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole JF: Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 1998, 29:913-917.
  15. Green HM, Li QJ, Martins-Green M: The Effects of Cigarette Smoke on Activation of Chemokines [abstract]. Mol Biol of the Cell 1999, 10(Suppl):2463.
  16. Wong LS, Green HM, Martins-Green M: Cigarette Smoke- Induced Changes in the Structure and Function of Fibroblasts [abstract]. Mol Biol of the Cell 1999, 10 (Suppl):1719.
  17. Wong LS, Martins-Green M: Differential effects of active and passive cigarette smoke on febroblasts, cells that are critical for proper healing [abstract]. Mol Biol of the Cell 2001, 12(Suppl):1213.
  18. Horuk R: Chemoattractant Ligands and Their Receptors. In Pharmacology and Toxicology: Basic and Clinical Aspects Edited by: Hollinger MA. N.Y, CRC Press; 1996:377.
  19. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B: JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 1992, 70:314-325.
  20. Wysocki SJ, Zheng MH, Smith A, Lamawansa MD, Iacopetta BJ, Robertson TA, Papadimitriou JM, House AK, Norman PE: Monocyte chemoattractant protein-1 gene expression in injured pig artery coincides with early appearance of infiltrating monocyte/ macrophages. J Cell Biochem 1996, 62:303-313.
  21. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999, 19:1518-1525.
  22. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773-778.
  23. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
  24. Griffith RB, Standafer S: Simultaneous mainstream-sidestream smoke exposure systems II. The rat exposure system. Toxicology 1985, 35:13-24.
  25. Linton MF, Farese RV Jr., Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG: Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein( a). J Clin Invest 1993, 92:3029-3037.
  26. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL: Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998, 101:1084-1093.
  27. Nishina PM, Verstuyft J, Paigen B: Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990, 31:859-869.
  28. Purcell-Huynh DA, Farese RV Jr., Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG: Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995, 95:2246-2257.
  29. Mayes RW: ACP Broadsheet No 142: November 1993. Measurement of carbon monoxide and cyanide in blood. J Clin Pathol 1993, 46:982-988.
  30. Rodkey FL, Hill TA, Pitts LL, Robertson RF: Spectrophotometric measurement of carboxyhemoglobin and methemoglobin in blood. Clin Chem 1979, 25:1388-1393. 31. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
  31. Carr TP, Andresen CJ, Rudel LL: Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993, 26:39-42.
  32. Wong LS, Green HM, Feugate JE, Yadav M, Nothnagel EA, Martins- Green M: Effects of "second-hand" smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol 2004, 5:13.
  33. Gairola CG, Drawdy ML, Block AE, Daugherty A: Sidestream cigarettesmoke accelerates atherogenesis in apolipoprotein E-/- mice. Atherosclerosis 2001, 156:49-55.
  34. Mullick AE, McDonald JM, Melkonian G, Talbot P, Pinkerton KE,Rutledge JC: Reactive carbonyls from tobacco smoke increasearterial endothelial layer injury. Am J Physiol Heart Circ Physiol2002, 283:H591-7.
  35. Nazaroff WW, Singer BC: Inhalation of hazardous air pollutantsfrom environmental tobacco smoke in US residences. J ExpoAnal Environ Epidemiol 2004, 14 Suppl 1:S71-7.
  36. Scherer G: Carboxyhemoglobin and thiocyanate as biomarkersof exposure to carbon monoxide and hydrogen cyanidein tobacco smoke. Exp Toxicol Pathol 2006, 58:101-124.
  37. Koul A, Singh A, Sandhir R: Effect of alpha-tocopherol on thecardiac antioxidant defense system and atherogenic lipids incigarette smoke-inhaling mice. Inhal Toxicol 2003, 15:513-522.
  38. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, MatsubaraK: cDNA cloning and expression of a novel adipose specificcollagen-like factor, apM1 (AdiPose Most abundantGene transcript 1). Biochem Biophys Res Commun 1996,221:286-289.
  39. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, HottaK, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T,Matsuzawa Y: Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation1999, 100:2473-2476.
  40. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, IshigamiM, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M,Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocytederivedplasma protein, adiponectin, suppresses lipid accumulationand class A scavenger receptor expression inhuman monocyte-derived macrophages. Circulation 2001,103:1057-1063.
  41. Zhao B, Stavchansky SA, Bowden RA, Bowman PD: Effect of interleukin-1beta and tumor necrosis factor-alpha on geneexpression in human endothelial cells. Am J Physiol Cell Physiol2003, 284:C1577-83.
  42. Parry GC, Martin T, Felts KA, Cobb RR: IL-1beta-induced monocytechemoattractant protein-1 gene expression in endothelialcells is blocked by proteasome inhibitors. ArteriosclerThromb Vasc Biol 1998, 18:934-940.
  43. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, RichelsenB: Regulation of adiponectin by adipose tissue-derivedcytokines: in vivo and in vitro investigations in humans. Am JPhysiol Endocrinol Metab 2003, 285:E527-33.
  44. Hansson GK: Cell-mediated immunity in atherosclerosis. CurrOpin Lipidol 1997, 8:301-311.
  45. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, KwiterovichPO Jr.: Association of coronary atherosclerosis with hyperapobetalipoproteinemia[increased protein but normal cholesterollevels in human plasma low density (beta)lipoproteins]. Proc Natl Acad Sci U S A 1980, 77:604-608.
  46. Teng B, Sniderman AD, Soutar AK, Thompson GR: Metabolic basisof hyperapobetalipoproteinemia. Turnover of apolipoproteinB in low density lipoprotein and its precursors and subfractionscompared with normal and familialhypercholesterolemia. J Clin Invest 1986, 77:663-672.
  47. Sniderman A, Brown BG, Stewart BF, Cianflone K: From familialcombined hyperlipidemia to hyperapoB: unravelling theoverproduction of hepatic apolipoprotein B. Curr Opin Lipidol1992, 3:137-142.
  48. Neufeld EJ, Mietus-Snyder M, Beiser AS, Baker AL, Newburger JW:Passive cigarette smoking and reduced HDL cholesterol levelsin children with high-risk lipid profiles. Circulation 1997,96:1403-1407.
  49. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, UchidaS, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, KomedaK, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K,Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T: Globular adiponectinprotected ob/ob mice from diabetes and ApoEdeficientmice from atherosclerosis. J Biol Chem 2003,278:2461-2468.
  50. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M,Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T,Funahashi T, Matsuzawa Y: Adiponectin reduces atherosclerosisin apolipoprotein E-deficient mice. Circulation 2002,106:2767-2770.
  51. Miyazaki T, Shimada K, Mokuno H, Daida H: Adipocyte derivedplasma protein, adiponectin, is associated with smoking statusin patients with coronary artery disease. Heart 2003,89:663.
  52. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, KusuharaM, Nishida Y, Iwakura Y, Ohsuzu F: Deficiency of interleukin-1 receptor antagonist promotes neointimal formation afterinjury. Circulation 2003, 108:516-518.
  53. Trinchieri G, Wysocka M, D'Andrea A, Rengaraju M, Aste-AmezagaM, Kubin M, Valiante NM, Chehimi J: Natural killer cell stimulatoryfactor (NKSF) or interleukin-12 is a key regulator ofimmune response and inflammation. Prog Growth Factor Res1992, 4:355-368.
  54. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK,Warrier RR, Pham N, Fogelman AM, Modlin RL: Cross-regulatoryroles of interleukin (IL)-12 and IL-10 in atherosclerosis. J ClinInvest 1996, 97:2130-2138.
  55. Mori M, Hara M, Wada I, Hara T, Yamamoto K, Honda M, NaramotoJ: Prospective study of hepatitis B and C viral infections, cigarettesmoking, alcohol consumption, and other factorsassociated with hepatocellular carcinoma risk in Japan. Am JEpidemiol 2000, 151:131-139.
  56. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, ErlingerS, Rueff B, Valla DC, Degos F: Cigarette smoking and hepaticlesions in patients with chronic hepatitis C. Hepatology 2001,34:121-125.
  57. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T,Angulo P: Effect of changes on body weight and lifestyle innonalcoholic fatty liver disease. J Hepatol 2005, 43:1060-1066.